Dov Goldstein has more than two decades of experience in the biopharmaceutical industry as a venture capital investor, an executive and a member of the boards of directors of a number of successful companies including ADMA Biologics (ADMA), Cempra Pharmaceuticals (CEMP), Durata Therapeutics, and Loxo Oncology (LOXO). The companies where Goldstein has played a leadership role have resulted in the approval of 2 drugs: Eraxis (anidulafungin) and Dalvance (dalbavancin. Goldstein is currently the chief financial officer, chief business officer, and director of Indapta Therapeutics. He currently serves on the board of RIGImmune, a Yale start-up developing the work of Professors Anna Pyle and Akiko Iwasaki. Goldstein was the chief financial officer of Schrödinger, LLC from 2017 to 2018. Goldstein served as a Managing Partner at Aisling Capital, a healthcare dedicated private investment firm, from 2014 to October 2017, Partner from 2008 to 2014 and a Principal at Aisling Capital from 2006 to 2008. Goldstein served as the chief financial officer of Loxo Oncology, Inc. between July 2014 and January 2015, and was its acting chief financial officer from January 2015 to May 2015. From 2000 to 2005, Goldstein served as chief financial officer of Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005, and helped lead the M&A process. Prior to joining Vicuron, Goldstein was director of venture analysis at HealthCare Ventures. Goldstein received a B.S. from Stanford University, an MBA from Columbia Business School and an M.D. from Yale School of Medicine.